NCT06334120View on ClinicalTrials.gov

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Non-metastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate Cancer
Interventions
DRUG

Darolutamide (Nubeqa, BAY1841788)

The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.

Trial Locations (1)

Unknown

RECRUITING

Multiple locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY